Cytori Therapeutics
Cytori ein riesiger Markt auftun.
If a link is established, French social security will pay for all women with the implants to have them removed, but only fund surgery to replace them in cases where women have had reconstructive surgery, for example after a mastectomy, Berra said.
French health officials said no direct link had been established between the implants and the eight cancer cases. However, the newspaper Liberation reported that the institute's head had already decided to recommend that all 30,000 women have them surgically removed.
The paper added that up to 300,000 women worldwide may have received PIP implants.
A French court is also investigating the death in 2010 of one patient that may be linked to an implant.
PIP implants contained a gel that became lumpy and granular, increasing the risk that the pouch would tear and leak gel into the patient's body.
Alexandra Blachere, head of an advocacy group for PIP implant patients, said all victims should be offered replacements.
"Taking out the implants because they are dangerous is well and good, but we cannot leave women in a state of psychological suffering afterwards, so it's necessary to reimplant, whatever the cost," she told journalists.
More than 2,000 complaints by women wearing PIP implants have been lodged since March 2010.
(Reporting By Gerard Bon and Patrick Vignal; writing by Nick Vinocur; Editing by Ben Harding)
http://www.reuters.com/article/2011/12/20/...ts-idUSTRE7BJ2AF20111220
SAN DIEGO, CA -- (MARKET WIRE) -- 11/30/11 -- Cytori's (NASDAQ: CYTX) Celution® One System, the next-generation device of the Company's Celution® platform, has been granted CE Mark approval. Celution® One is tailored specifically for the hospital as a platform device with potential life-critical applications across multiple specialties. The Celution® platform is a GMP-compliant technology that extracts and concentrates a patient's own stem and progenitor cells from adipose (fat) at the point-of-care.
The Celution® One is intended for hospital-based use with key improvements including greater cell yield, greater range of processing volumes and faster processing times, increasing the versatility and efficiencies of potential treatments. Additionally, it contains new features for improved operator ease-of-use.
"Approval of Celution® One in Europe is an important achievement that lays the foundation for further growth in the European hospital market," said Christopher J. Calhoun, Chief Executive Officer of Cytori. "In addition to offering the device to hospitals in Europe, we are using the Celution® One in our pivotal heart attack trial, ADVANCE, with the goal of seeking expanded market access through broader indications-for-use and subsequent reimbursement applications."
Dear Investors,
The United Kingdom’s National Institute for Health and Clinical Excellence (NICE) yesterday issued interventional procedure guidance for breast reconstruction following cancer treatment (http://guidance.nice.org.uk/IP/845). It concludes lipomodelling (autologous fat grafting) is a safe and effective option to restore volume and contour defects after breast conserving surgery (lumpectomy). It notes that devices are currently being introduced, which aim to concentrate adipose stem cells and enrich adipose tissue in lipomodelling and encourages the generation of additional outcome data for such procedures.
What it Means to Cytori: The guidance is a positive and important development for Cytori’s pursuit of payment (reimbursement) in the UK for its Celution-based breast reconstruction procedure. The next step in the process is to apply to the Medical Technology Advisory Committee to NICE. This committee provides formal product specific certification of clinical and economic benefit. This process typically takes nine to 12 months. A positive outcome will facilitate use of the Celution® System and related consumables for breast reconstruction across the UK in both private and National Healthcare System hospitals.
Given the UK and NICE’s influence as a leading reference, this effort should help further our progress in the other countries throughout Europe where we are also currently seeking payment or reimbursement. An estimated 12,000 breast reconstruction surgeries are performed each year in the UK alone and 125,000 throughout Europe.
Background: NICE is a government organization that provides guidance on treatments and procedures to the National Health System (NHS), sets quality standards and manages a national database to improve health in the U.K. NICE guidelines are most frequently issued on procedures that are relatively new and NICE is increasingly looked to across Europe as a leading voice in healthcare and economic analysis.
Based on the available evidence and the views of Specialist Advisers, NICE’s Interventional Procedures Advisory Committee reported the procedure is effective, noting that there is no published evidence of increased recurrence, and there are not expected to be any significant issues with imaging interference given current lipomodelling techniques and expert interpretation. NICE guidance strongly influences which procedures and treatments are offered by the U.K.’s National Health System.
This guidance is encouraging since few options are currently available to lumpectomy patients and use of lipomodelling (including cell-enriched) has thus far been limited because of uncertainties among doctors about the procedures’ risks and its potential to interfere with imaging of the breast for cancer surveillance.
Professional breast care organizations in the UK had formally acknowledged this development with the issuance of their own lipomodelling guidelines including a more extensive section on cell-enriched fat transfer.
Regards,
Tom Baker
Cytori Therapeutics
Investor Relations
Optionen
| Boardmail an "ecki" |
Wertpapier: Cytori Therapeutics |
CYTX Awarded Patents to Treat Wounds with Stem Cells
February 6, 2012
Cytori (NASDAQ: CYTX) has been issued US Patent No. 8,105,580 (the ‘580 patent) covering methods of using adipose-derived stem and regenerative cells extracted by self-contained adipose tissue processing devices such as our Celution® System, to heal wounds, including non-healing diabetic wounds. The ‘580 patent has 33 claims, which include wound healing by i) fresh cells, which are uncultured; ii) cells combined with an additive or reagent; and iii) cells that have been combined with one or more angiogenic factors.
This follows our December 2011 issuance in Europe of a broader patent (EP1778833) that covers adipose-derived stem and regenerative cells also for the treatment of wounds, whereby the adipose may be processed by any method (i.e. device independent). This is commercially relevant today, as Celution® is approved in Europe for treating specific types of chronic wounds. We also have wound-related patents in Japan and India giving us patent protection for this indication in four of the largest global healthcare markets.
Chronic wounds represent a major burden on the healthcare system and there is a need for novel treatments, such as cell therapy. An example of how the Celution® System could potentially address this market is offered in the case report, “Adipose Derived Regenerative Cell Therapy for Treating a Diabetic Wound.”
Today we now have 40 issued patents worldwide, with more than 100 patent applications pending. Please review our latest barrier-to-entry fact sheet for an updated overview of our strategy for protecting our competitive position and a complete table of our issued patents.
hier der link dazu:
http://ir.cytori.com/InvestorRelations/blog.cfm
San Diego Source > News > Cytori could get $531M from Lorem licensing deal News > Cytori could get
... (automatisch gekürzt) ...
http://www.sddt.com/news/...1M+from+Lorem+licensing+deal#.Unja5nAyJZc
Moderation
Zeitpunkt: 06.11.13 12:42
Aktion: Kürzung des Beitrages
Kommentar: Urheberrechtsverletzung, ggf. Link-Einfügen nutzen
Zeitpunkt: 06.11.13 12:42
Aktion: Kürzung des Beitrages
Kommentar: Urheberrechtsverletzung, ggf. Link-Einfügen nutzen
Optionen
| Boardmail an "ecki" |
Wertpapier: Cytori Therapeutics |
Moderation
Zeitpunkt: 07.11.13 08:37
Aktionen: Löschung des Beitrages, Nutzer-Sperre für 1 Tag
Kommentar: Einstellen eines zuvor gelöschten Postings - Beleidigung im 1. Absatz. Außerdem bitte nur kurz zitieren!
Zeitpunkt: 07.11.13 08:37
Aktionen: Löschung des Beitrages, Nutzer-Sperre für 1 Tag
Kommentar: Einstellen eines zuvor gelöschten Postings - Beleidigung im 1. Absatz. Außerdem bitte nur kurz zitieren!
Optionen
| Boardmail an "ecki" |
Wertpapier: Cytori Therapeutics |
VIEL ERFOLG!
komisch dass sich in D niemand dafür interessiert, man zockt doch
sonst weltmeisterlich in US Biowerten herum. Dabei unterscheidet sich
Cytori kaum von den scheinbar so populären Titeln wie Aeterna und anderen.
Der Chartverlauf dieser Aktien ähnelt denen von AEZS.
Hier ging es knapp unter 0,40$ (0,30€) die Umsätze in USA sind nicht ohne.
http://charting.nasdaq.com/ext/...-03NA000000CYTX-&WD=539-HT=395-
Man könnte meinen dass die 0,40$ eine Tieflinie markiert.
Wenn ein Investor wie Lorem Vascular 8 Millionen Aktien für 3 $ pro Aktie
gekauft hat, kann man ihn nur bedauern, zeugt deutlich von Fehleinschätzung.
Hier die heutige News:
http://ih.advfn.com/...pid=nmona&article=64740829&symbol=CYTX
Optionen
| Boardmail an "chacha1" |
Wertpapier: Cytori Therapeutics |